Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats

Kyohei Nishimura, Nao Nakano, Vishwajit Surchowdhury, Masako Kaneto, Mikinori Torii, Masa aki Hattori, Nobuhiko Yamauchi, Motoyuki Kawai

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

BACKGROUND: The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats. METHODS: GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17. RESULTS: Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone. CONCLUSIONS: High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.

元の言語英語
ページ(範囲)164-169
ページ数6
ジャーナルBirth Defects Research Part B - Developmental and Reproductive Toxicology
98
発行部数2
DOI
出版物ステータス出版済み - 4 1 2013

Fingerprint

Embryonic and Fetal Development
Placentation
Peroxisome Proliferator-Activated Receptors
Rats
Pregnancy
Placenta
Oral Administration
GW 501516
Glycogen
Pregnancy Outcome
Endometrium
Toxicity
Cesarean Section

All Science Journal Classification (ASJC) codes

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

これを引用

Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats. / Nishimura, Kyohei; Nakano, Nao; Surchowdhury, Vishwajit; Kaneto, Masako; Torii, Mikinori; Hattori, Masa aki; Yamauchi, Nobuhiko; Kawai, Motoyuki.

:: Birth Defects Research Part B - Developmental and Reproductive Toxicology, 巻 98, 番号 2, 01.04.2013, p. 164-169.

研究成果: ジャーナルへの寄稿記事

Nishimura, Kyohei ; Nakano, Nao ; Surchowdhury, Vishwajit ; Kaneto, Masako ; Torii, Mikinori ; Hattori, Masa aki ; Yamauchi, Nobuhiko ; Kawai, Motoyuki. / Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats. :: Birth Defects Research Part B - Developmental and Reproductive Toxicology. 2013 ; 巻 98, 番号 2. pp. 164-169.
@article{b77e8b30ee054a0eb5da420457ed8177,
title = "Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats",
abstract = "BACKGROUND: The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats. METHODS: GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17. RESULTS: Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone. CONCLUSIONS: High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.",
author = "Kyohei Nishimura and Nao Nakano and Vishwajit Surchowdhury and Masako Kaneto and Mikinori Torii and Hattori, {Masa aki} and Nobuhiko Yamauchi and Motoyuki Kawai",
year = "2013",
month = "4",
day = "1",
doi = "10.1002/bdrb.21052",
language = "English",
volume = "98",
pages = "164--169",
journal = "Teratogenesis Carcinogenesis and Mutagenesis",
issn = "1542-9733",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats

AU - Nishimura, Kyohei

AU - Nakano, Nao

AU - Surchowdhury, Vishwajit

AU - Kaneto, Masako

AU - Torii, Mikinori

AU - Hattori, Masa aki

AU - Yamauchi, Nobuhiko

AU - Kawai, Motoyuki

PY - 2013/4/1

Y1 - 2013/4/1

N2 - BACKGROUND: The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats. METHODS: GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17. RESULTS: Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone. CONCLUSIONS: High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.

AB - BACKGROUND: The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats. METHODS: GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17. RESULTS: Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone. CONCLUSIONS: High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.

UR - http://www.scopus.com/inward/record.url?scp=84876079496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876079496&partnerID=8YFLogxK

U2 - 10.1002/bdrb.21052

DO - 10.1002/bdrb.21052

M3 - Article

C2 - 23460579

AN - SCOPUS:84876079496

VL - 98

SP - 164

EP - 169

JO - Teratogenesis Carcinogenesis and Mutagenesis

JF - Teratogenesis Carcinogenesis and Mutagenesis

SN - 1542-9733

IS - 2

ER -